Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / FAS

FAS

Basics

Aliases:
This biomarker is also known as:
  • FASLG receptor,
  • FAS 827dupA,
  • TNFRSF6,
  • CD95,
  • Fas (TNF receptor superfamily, member 6),
  • apoptosis antigen 1,
  • APT1,
  • FASTM,
  • CD95 antigen,
  • tumor necrosis factor receptor superfamily member 6,
  • apoptosis-mediating surface antigen FAS,
  • FAS1,
  • FAS (Ab2),
  • Apo-1 antigen,
  • FAS (Ab1),
  • tumor necrosis factor receptor superfamily, member 6,
  • Apoptosis-mediating surface antigen FAS,
  • APO-1,
  • ALPS1A,
  • Fas AMA,
  • Delta Fas/APO-1/CD95,
  • APO-1 cell surface antigen,

View in BioMuta

Description…

FAS is a member of the TNF-receptor superfamily. The FAS protein is a receptor for TNFSF6/FASLG and has been shown to play a central role in the physiological regulation of programmed cell death, and has been implicated in the pathogenesis of various malignancies and diseases of the immune system. Several alternatively spliced transcript variants have been described, some of which are candidates for nonsense-mediated mRNA decay (NMD). The isoforms lacking the transmembrane domain may negatively regulate the apoptosis mediated by the full length isoform.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: FAS

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

No additional breast data available.

Performance Comment

FAS was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Ovary

Attributes

Phase: Three
QA State: Under Review

Overview

APO-1/Fas receptor (FasR) is a cell surface receptor that, when activated, triggers apoptosis. It has been postulated that this receptor may be involved in the clearance of benign ovarian epithelial inclusion cysts (IC). An observed decreased expression of FasR in malignant ovarian epithelial neoplasms as compared with benign ovarian epithelial lesions suggests that a decreased sensitivity to Fas-mediated apoptosis may be involved in ovarian epithelial carcinogenesis.

Performance Comment

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.